Health & Fitness
Health and FitnessHealth and Fitness 
Mon, February 21, 2011
Sun, February 20, 2011
Fri, February 18, 2011
00 a.m. ET to Discuss Financial Results for the Fourth Quarter and Year Ended 2010
LEXINGTON, Mass.--([ BUSINESS WIRE ])--AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced it will report unaudited consolidated financial results for the fourth quarter and year ended December 31, 2010 before the U.S. financial markets open on February 25, 2011. The announcement will be followed by a conference call and webcast with slides at 8:00 a.m. ET during which management will discuss the companya™s financial results, commercial progress and development programs.
To access the conference call via telephone, please dial (877) 412-6083 from the United States or (702) 495-1202 for international access. A telephone replay will be available from approximately 11:00 a.m. ET on February 25, 2011 through midnight February 28, 2011. To access a replay of the conference call, dial (800) 642-1687 from the United States or (706) 645-9291 for international access. The pass code for the live call and the replay is 44645136.
The call will be webcast with slides and accessible through the Investors section of the Companya™s website at [ www.amagpharma.com ]. The webcast replay will be available from approximately 11:00a.m. ET on February 25, 2011 through midnight March 25, 2011.
About AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia. AMAG manufactures and sells Feraheme® (ferumoxytol) Injection for intravenous use. For additional company or product information, please visit [ www.amagpharma.com ] or [ http://feraheme.com ].
Feraheme is a registered trademark of AMAG Pharmaceuticals, Inc.